CW June 2002
Volume 11Issue Number 6 June 2002 ISSN 10593802 Gleevec Continues to Succeed Against CML and GISTThe fastest approved drug in FDA history, STI-571 (Gleevec or imatinib), continues to live up to the title of the ?poster boy? for targeted therapy. Clinical trials show that this daily oral drug may prevent early chronic myeloid leukemia (CML) from progressing and appears to have long-lasting benefits in treating gastrointestinal stromal tumors (GIST).
Go to Previous Page Go to Next Page Source & Additional Reading American Society of Clinical Oncology annual meeting in Orlando. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW June 2002Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
